Short answer
Neurogene Inc. (NGNE) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 7.01 (Regulation FD Disclosure). Completion of dosing in registrational Embolden trial for NGN-401, a Rett syndrome treatment candidate.
Neurogene Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Completion of dosing in registrational Embolden trial for NGN-401, a Rett syndrome treatment candidate
- Dosing milestone advances NGN-401 toward potential regulatory submission
- Updated corporate presentation furnished as Exhibit 99.2, likely containing refreshed development and corporate information
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurogene Inc. 8-K filings
Get the next NGNE 8-K as it lands
Follow NGNE for push alerts, or ask the research agent what this filing means.